Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/26/2025 | Mkt Perform → Outperform | Bernstein | ||
| 2/25/2025 | Mkt Perform → Outperform | Bernstein | ||
| 2/24/2025 | $100.00 → $180.00 | Equal-Weight → Overweight | Morgan Stanley | |
| 12/17/2024 | $12.00 → $13.00 | Underweight → Neutral | Analyst | |
| 12/13/2024 | $18.00 → $21.00 | Equal-Weight → Overweight | Morgan Stanley | |
| 12/9/2024 | $18.00 | Neutral → Buy | BofA Securities | |
| 10/7/2024 | $145.00 | Neutral → Outperform | Macquarie | |
| 7/22/2024 | $12.00 → $18.00 | Underperform → Neutral | BofA Securities |
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
Bernstein upgraded Alibaba from Mkt Perform to Outperform
Bernstein upgraded Alibaba from Mkt Perform to Outperform
Morgan Stanley upgraded Alibaba from Equal-Weight to Overweight and set a new price target of $180.00 from $100.00 previously
SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Platform Trial participants. The analyses further substantiate that treatment with CNM-Au8® 30 mg delivers a significant survival benefit for people living with ALS. New Survival AnalysesThe analyses compared survival in participants who received CNM-Au8 30 mg (Regimen C)
Leveraging Reasoning models to Simplify Market Entry and Global Sourcing for SMEs HANGZHOU, China, March 10, 2025 /PRNewswire/ -- Alibaba International Digital Commerce Group ("Alibaba International") announced today that its artificial intelligence (AI)-driven business-to-business (B2B) search engine, Accio, has surpassed 1 million users within five months of launch. To further empower small and medium-sized enterprises (SMEs), two new features—Business Research and Deep Search—are now available, offering AI-driven solutions for market entry and global sourcing. Recent AI Momentum at Alibaba Accio is an AI-native application designed to simplify global trade for SMEs. Built on Alibaba's fo
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings. Date: March 18, 2025Time of Presentation: 9:20 am PSTFormat: Virtual Fireside Chat1x1 Meetings: Please contact your Roth representative. A webcast of the presentation will be available on the "E
4 - TaskUs, Inc. (0001829864) (Issuer)
4 - TaskUs, Inc. (0001829864) (Issuer)
4 - TaskUs, Inc. (0001829864) (Issuer)
8-K - Clene Inc. (0001822791) (Filer)
S-8 - Bioventus Inc. (0001665988) (Filer)
10-K - Bioventus Inc. (0001665988) (Filer)
SC 13G/A - Alibaba Group Holding Ltd (0001577552) (Filed by)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs
TaskUs, Inc. (NASDAQ:TASK), a leading provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, today announced its results for the fourth quarter and full year ended December 31, 2024. Fourth quarter total revenue of $274.2 million, 17.1% year-over-year growth. Exceeding the top-end of our guidance by $4.9 million. Net Income of $8.9 million, Net Income margin of 3.2%. Adjusted Net Income of $28.5 million, Adjusted Net Income margin of 10.4%. Diluted EPS of $0.10, Adjusted EPS of $0.31. Adjusted EBITDA of $53.8 million, Adjusted EBITDA margin of 19.6%. Net cash provided by operating activities of $40.7 millio
New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvementFindings to form the basis for a Phase 3 program, anticipated to start in H2 2025 PARSIPPANY, N.J. and PARIS, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi today presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV'574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for
GREEN BAY, Wis., Dec. 19, 2024 /PRNewswire/ -- Associated Banc-Corp (NYSE: ASB) ("Associated" or "Company") today announced the addition of four experienced relationship managers to the company's growing commercial banking team. The hiring of Stacy Quick, Kevin Kopaska, Mike Hauswirth and Scott Rothenbush is a continuation of Associated's multi-year strategic growth plan designed to bolster talent in key focus markets, expand commercial capabilities, and deepen relationships with new and existing clients. "We're thrilled to have Stacy, Kevin, Mike and Scott join our team as we
MILWAUKEE, Dec. 12, 2024 /PRNewswire/ -- Associated Banc-Corp (NYSE: ASB) ("Associated") announced today the appointment of Steven Zandpour to its Executive Leadership Team (ELT), effective January 1, 2025. Zandpour, 48 will be executive vice president, deputy head of Consumer and Business Banking, Associated Bank, reporting directly to David Stein, executive vice president, head of Consumer and Business Banking and Madison Market president. "Steve's people-first leadership style and dedication to colleagues and customers has helped us grow our business and improve our custome
Sorenson will transition into the role of executive vice president, managing director and CEO, Associated Trust Company on February 1, 2025 GREEN BAY, Wisc., Dec. 11, 2024 /PRNewswire/ -- Associated Banc-Corp (NYSE:ASB) ("Associated") announced today the appointment of Heath Sorenson, MBA, CFP®, CFIRS™, CTOP, to executive vice president, managing director, Associated Trust Company. Effective February 1, 2025, Sorenson will become executive vice president, managing director and chief executive officer, Associated Trust Company and John Thayer, current chief executive officer and executive vice president of Associated Trust Company, will transition into the role of executive vice president and